Cargando…

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation

Detalles Bibliográficos
Autores principales:	Correnti, Colin E., Laszlo, George S., de van der Schueren, Willem J., Godwin, Colin D., Bandaranayake, Ashok, Busch, Melanie A., Gudgeon, Chelsea J., Bates, Olivia M., Olson, James M., Mehlin, Christopher, Walter, Roland B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943151/ https://www.ncbi.nlm.nih.gov/pubmed/29588544 http://dx.doi.org/10.1038/s41375-018-0014-3

Ejemplares similares

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2021)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
por: Kujawski, Maciej, et al.
Publicado: (2019)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
por: Yang, Xiao-mei, et al.
Publicado: (2023)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
por: Zhu, Winston M, et al.
Publicado: (2023)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
por: Yuraszeck, T, et al.
Publicado: (2017)

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Publicado: (2021)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities
por: Morcos, Peter N., et al.
Publicado: (2020)

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
por: Simão, Diana C., et al.
Publicado: (2023)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
por: Loh, Han Ping, et al.
Publicado: (2023)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
por: Bi, Yanyu, et al.
Publicado: (2017)

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
por: Heidbuechel, Johannes P. W., et al.
Publicado: (2021)

Development of a bispecific immune engager using a recombinant malaria protein
por: Nordmaj, Mie A., et al.
Publicado: (2021)

Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma
por: Hua, Gwen, et al.
Publicado: (2022)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
por: Kühl, Lennart, et al.
Publicado: (2023)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
por: Shin, Ha Gyeong, et al.
Publicado: (2022)

Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
por: Carrara, Stefania C., et al.
Publicado: (2022)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies
por: Shepherd, Alex, et al.
Publicado: (2023)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7p0ig2okjfftomj71bhmc1ms9u